All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The SOT Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the SOT Hub cannot guarantee the accuracy of translated content. The SOT Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Solid Organ Transplantation Hub is an independent medical education platform, sponsored by Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View solid organ transplantation content recommended for you
The diagnostic value of dd-cfDNA in liver transplant rejection
Results from a systematic review and meta-analysis assessing the diagnostic accuracy of donor-derived cell-free DNA (dd-cfDNA) for rejection following liver transplantation were published in Transplantation Reviews by Zhang et al. The aim of this study was to evaluate the diagnostic performance and value of dd-cfDNA at different thresholds.
Key data: Overall, 11 studies comprising 901 patients were included. Meta-analyses demonstrated that dd-cfDNA achieved a pooled sensitivity of 0.90 (95% confidence interval [CI], 0.76–0.96) and a pooled specificity of 0.90 (95% CI, 0.82–0.94) for diagnosing rejection. The combined positive likelihood ratio (PLR) was 8.95 (95% CI, 5.39–13.69), with a negative likelihood ratio (NLR) of 0.11 (95% CI, 0.04–0.28). The diagnostic odds ratio (DOR) was 77.39 (95% CI, 35.85–167.03), and the area under the curve (AUC) was 0.95 (95% CI, 0.93–0.97). Heterogeneity was identified across studies in sensitivity (I2 = 76.19%), specificity (I2 = 80.79%), and DOR (I2 = 88.29%).
Key learning: dd-cfDNA demonstrates promising diagnostic value as a complementary, non-invasive biomarker for rejection following liver transplantation. However, heterogeneity in diagnostic thresholds and methodologies highlights the need for further investigation.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.jpeg)
